Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: A meta-analysis

DNA and Cell Biology

Volumn 31, Issue 2, 2012, Pages 230-237

  Hu, Yi ^a   Jiang, Lan ^b   Zheng, Jian ^b   You, Yonghe ^b   Zhou, Yifeng ^b   Jiao, Shunchang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P73;

ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CAUCASIAN; COLORECTAL CANCER; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ESOPHAGUS CARCINOMA; ETHNIC DIFFERENCE; EXON; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENOTYPE; HEAD AND NECK CARCINOMA; HETEROZYGOTE; HODGKIN DISEASE; HUMAN; JAPANESE; KOREAN; LEUKOPLAKIA; LUNG CANCER; MEDICAL LITERATURE; MELANOMA; MOUTH CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER;

ALGORITHMS; AT RICH SEQUENCE; BASE COMPOSITION; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GC RICH SEQUENCE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS; NUCLEAR PROTEINS; POLYMORPHISM, GENETIC; REVIEW LITERATURE AS TOPIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84863057018     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1305     Document Type: Article

References (44)

1. Arfaoui, A.T., Kriaa, L.B., El Hadj Oel, A., Ben Hmida, M.A., Khiari, M., Khalfallah, T., et al. (2010). Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients. Virchows Arch 457, 359-368.
2. Chen, X., Sturgis, E.M., El-Naggar, A.K., Wei,Q., and Li, G. (2008b). Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis 29, 2120-2125.
3. Chen, X., Sturgis, E.M., Etzel, C.J., Wei, Q., and Li, G. (2008a). p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer 113, 3307-3314.
4. Choi, J.E., Kang, H.G., Chae, M.H., Kim, E.J., Lee, W.K., Cha, S.I., et al. (2006). No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet 44, 543-550.
5. Concin, N., Becker, K., Slade, N., Erster, S., Mueller-Holzner, E., Ulmer, H., et al. (2004). Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64, 2449-2460. (Pubitemid 38523899)
6. De Feo, E., Persiani, R., La Greca, A., Amore, R., Arzani, D., Rausei, S., et al. (2009). A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res 675, 60-65.
7. Egger, M., Davey Smith, G., Schneider, M., and Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634. (Pubitemid 27387172)
8. Flores, E.R., Tsai, K.Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., et al. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564. (Pubitemid 34288861)
9. Galli, P., Cadoni, G., Volante, M., De Feo, E., Amore, R., Giorgio, A., et al. (2009). A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer 9, 137.
10. Ge, H., Wang, Y.M., Cao, Y.Y., Chen, Z.F., Wen, D.G., Guo, W., et al. (2007). The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus 20, 290-296. (Pubitemid 47054757)
11. Grob, T.J., Novak, U., Maisse, C., Barcaroli, D., Luthi, A.U., Pirnia, F., et al. (2001). Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8, 1213-1223. (Pubitemid 34048476)
12. Haber, D.A., and Fearon, E.R. (1998). The promise of cancer genetics. Lancet 351 Suppl 2, SII1-SII8.
13. Hishida, A., Matsuo, K., Tajima, K., Ogura, M., Kagami, Y., Taji, H., et al. (2004). Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma 45, 957-964. (Pubitemid 38444672)
14. Hu, Z., Miao, X., Ma, H., Tan, W., Wang, X., Lu, D., et al. (2005). Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer 114, 455-460. (Pubitemid 40279969)
15. Huang, X.E., Hamajima, N., Katsuda, N., Matsuo, K., Hirose, K., Mizutani, M., et al. (2003). Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10, 307-311.
16. Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T., and Ikawa, S. (2002). Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 62, 636-641. (Pubitemid 34126932)
17. Jost, C.A., Marin, M.C., and Kaelin, W.G., Jr. (1997). p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191-194. (Pubitemid 27400602)
18. Kaelin, W.G., Jr. (1999). The emerging p53 gene family. J Natl Cancer Inst 91, 594-598. (Pubitemid 29194044)
19. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C., Valent, A., et al. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819. (Pubitemid 27357971)
20. Kang, S., Wang, D.J., Li, W.S., Wang, N., Zhou, R.M., Sun, D.L., et al. (2009). Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer 19, 572-577.
21. Lau, J., Ioannidis, J.P., and Schmid, C.H. (1997). Quantitative synthesis in systematic reviews. Ann Intern Med 127, 820-826. (Pubitemid 27465551)
22. Lee, K.E., Hong, Y.S., Kim, B.G., Kim, N.Y., Lee, K.M., Kwak, J.Y., et al. (2010). p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol 16, 4448-4454.
23. Li, C., Chen, K., Liu, Z., Wang, L.E., Gershenwald, J.E., Lee, J.E., et al. (2008). Polymorphisms of TP53 Arg72Pro, but not p73 G4C14 > A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol 128, 1585-1588. (Pubitemid 351693182)
24. Li, G., Sturgis, E.M., Wang, L.E., Chamberlain, R.M., Amos, C.I., Spitz, M.R., et al. (2004b). Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 25, 1911-1916. (Pubitemid 39405910)
25. Li, G., Wang, L.E., Chamberlain, R.M., Amos, C.I., Spitz, M.R., and Wei, Q. (2004a). p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res 64, 6863-6866. (Pubitemid 39330992)
26. Liu, H.X., Cartegni, L., Zhang, M.Q., and Krainer, A.R. (2001). A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27, 55-58. (Pubitemid 32044518)
27. Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D.J., Smith, D.I., et al. (1998). Activation of p73 silent allele in lung cancer. Cancer Res 58, 2347-2349. (Pubitemid 28252692)
28. Misra, C., Majumder, M., Bajaj, S., Ghosh, S., Roy, B., and Roychoudhury, S. (2009). Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog 48, 790-800.
29. Moll, U.M., and Slade, N. (2004). p63 and p73: roles in development and tumor formation. Mol Cancer Res 2, 371-386. (Pubitemid 39031071)
30. Niwa, Y., Hamajima, N., Atsuta, Y., Yamamoto, K., Tamakoshi, A., Saito, T., et al. (2004). Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 205, 55-60. (Pubitemid 38230139)
31. Niwa, Y., Hirose, K., Matsuo, K., Tajima, K., Ikoma, Y., Nakanishi, T., et al. (2005). Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 219, 183-190. (Pubitemid 40269482)
32. Nomoto, S., Haruki, N., Kondo, M., Konishi, H., and Takahashi, T. (1998). Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58, 1380-1383. (Pubitemid 28193594)
33. Oswald, C., and Stiewe T. (2008). In good times and bad: p73 in cancer. Cell Cycle 7, 1726-1731. (Pubitemid 351988738)
34. Petitti, D.B. (1994). Of babies and bathwater. Am J Epidemiol 140, 779-782.
35. Pfeifer, D., Arbman, G., and Sun, X.F. (2005). Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis 26, 103-107. (Pubitemid 40207704)
36. Ryan, B.M., McManus, R., Daly, J.S., Carton, E., Keeling, P.W., Reynolds, J.V., et al. (2001). A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer 85, 1499-1503. (Pubitemid 34001580)
37. Sayan, A.E., Sayan, B.S., Findikli, N., and Ozturk, M. (2001). Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 20, 5111-5117. (Pubitemid 32844039)
38. Schabath, M.B., Wu, X., Wei, Q., Li, G., Gu, J., and Spitz, M.R. (2006). Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 15, 158-161.
39. Stiewe, T., Zimmermann, S., Frilling, A., Esche, H., and Putzer, B.M. (2002). Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 62, 3598-3602.
40. Tokuchi, Y., Hashimoto, T., Kobayashi, Y., Hayashi, M., Nishida, K., Hayashi, S., et al. (1999). The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br J Cancer 80, 1623-1629. (Pubitemid 29308646)
41. Wang, X.Q., Ongkeko, W.M., Lau, A.W., Leung, K.M., and Poon, R.Y. (2001). A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res 61, 1598-1603. (Pubitemid 34292593)
42. Weinberg, R.A. (1994). Oncogenes and tumor suppressor genes. CA Cancer J Clin 44, 160-170. (Pubitemid 24190197)
43. Woolf, B. (1955). On estimating the relation between blood group and disease. Ann Hum Genet 19, 251-253.
44. Zaika, A.I., Slade, N., Erster, S.H., Sansome, C., Joseph, T.W., and Pearl, M., et al. (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196, 765-780.